

# Medical Drug Formulary Recommendations

January 9, 2024

Recommendations by EBRx every 6 months

| Drug               | Treating Diagnosis  | EBRx Recommendation                         | Explanation   | Cost                        |
|--------------------|---|---|---|-----------------------------|
| <b>Adstiladrin</b> | Gene Therapy for bladder cancer                           | Exclude                                     | Lack of comparative data; less expensive alternatives   | 4 dose course:<br>\$288,000 |
| <b>Columvi</b>     | Diffuse Large B-cell Lymphoma                             | Exclude                                     | Efficacy is similar to epcoritamab but no QOL data  | \$208,598 per 6 months      |
| <b>Polivy</b>      | Diffuse Large B-cell Lymphoma                             | Exclude                                     | No QOL data   | \$119,000 per 6 cycles      |
| <b>Pombliti</b>    | Late onset Pompe disease                                  | Exclude                                     | Lacks meaningful clinical data  | \$51,408 per year           |
| <b>Qalsody</b>     | Amyotrophic lateral sclerosis (ALS) with mutation of SOD1 | Exclude                                     | Lacks meaningful clinical data, intrathecal route   | \$239,604 per year          |
| <b>Roctavian</b>   | Gene Therapy for severe Hemophilia A                      | Exclude                                     | Not cost effective, less expensive alternatives   | \$2.9M                      |
| <b>Vyjuvek gel</b> | Wounds from dystrophic epidermolysis bullosa (DEB)        | Exclude                                     | Small volume clinical trial, insufficient clinical benefit  | \$558,000 per year          |
| <b>Botox</b>       | Urinary Incontinence                                      | Cover with PA for Urinary Incontinence (UI) | Xeomin not FDA approved for UI. For all other FDA approved diagnosis, Xeomin is recommended due to rebate | \$760 per injection         |